Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland.
Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland; Department of General and Colorectal Surgery, Faculty of Medicine, Medical University of Lodz, Poland.
Crit Rev Oncol Hematol. 2021 Jan;157:103122. doi: 10.1016/j.critrevonc.2020.103122. Epub 2020 Oct 19.
In this review we focus on the pathophysiology of CRC-related pain and discuss currently applied pain management. Pain is a symptom reported by over 70 % of colorectal cancer (CRC) patients. It remains a feared and debilitating consequence of both cancer and cancer-related treatment. There are many options for pain management in CRC, consisting of intravenous, oral or topical medications. In order to address the full spectrum of pain, proper treatment should address the nociceptive, neuropathic and/or psychogenic pain component. Currently available methods do not bring pain relief to satisfying number of patients and, if used improperly, can cause a number of complications. Therefore, future treatments should focus primarily on alleviating pain, but also on reducing possible side effects. In this article we cover recent and promising pharmacological and non- pharmacological developments emerging in the field of CRC treatment.
在这篇综述中,我们重点介绍了与 CRC 相关疼痛的病理生理学,并讨论了目前应用的疼痛管理。疼痛是超过 70%的结直肠癌(CRC)患者报告的症状。它仍然是癌症及其相关治疗的一种令人恐惧和使人虚弱的后果。CRC 有许多疼痛管理的选择,包括静脉内、口服或局部药物。为了处理疼痛的全貌,适当的治疗应该解决伤害感受性、神经性和/或精神性疼痛成分。目前可用的方法并不能使足够数量的患者缓解疼痛,如果使用不当,会引起许多并发症。因此,未来的治疗应主要侧重于缓解疼痛,但也要减少可能的副作用。在本文中,我们涵盖了 CRC 治疗领域中出现的最新和有前途的药理学和非药理学进展。